Biosimilars | Gyros Protein Technologies immunoassays
Biosimilars
Confident biosimilar development starts here
Biosimilars are biologic medical products that are highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Unlike small-molecule generics, biologics are large, structurally complex proteins produced in living systems. As a result, even minor variations in cell lines, manufacturing processes, or formulation can influence critical quality attributes such as glycosylation patterns, higher-order structure, aggregation, and binding activity.
Regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency require comprehensive analytical comparability exercises to demonstrate biosimilarity. This demands robust, sensitive, and reproducible bioanalytical methods capable of detecting subtle differences between a biosimilar candidate and its reference product across multiple attributes - particularly functional binding and immunogenicity risk.
Why Gyrolab is ideal for biosimilar analysis
The Gyrolab platform from Gyros Protein Technologies is purpose-built for high-performance immunoassays that meet the demanding analytical requirements of biosimilar development
High sensitivity and wide dynamic range
Gyrolab’s nanoliter-scale microfluidic technology enables highly sensitive detection of binding interactions across a broad concentration range, supporting accurate quantification of low-abundance analytes and subtle potency differences.
Superior matrix tolerance
The flow-through format reduces background in complex matrices such as serum. This can negate potential specificity/selectivity issues that may be observed in patient samples e.g. Rheumatoid Arthritis.
Exceptional precision and reproducibility
Automated workflows minimize manual intervention and variability, delivering consistent results critical for comparability studies. Reliable reproducibility strengthens confidence when demonstrating equivalence between biosimilar and reference products.
Low sample and reagent consumption
The microfluidic format significantly reduces sample and reagent volumes - an important advantage when reference material is limited or costly.
Multiparametric binding and potency assessment
Gyrolab systems are well-suited for evaluating target binding, receptor interactions, and anti-drug antibody (ADA) responses. This supports comprehensive characterization of functional similarity and immunogenicity risk, both central to regulatory submissions.
Streamlined method transfer and scalability
Standardized assay protocols and automation facilitate method development, validation, and transfer across laboratories, ensuring consistency from early development through regulatory filing and post-approval lifecycle management.
By combining analytical rigor with operational efficiency, Gyrolab provides a powerful solution for biosimilar programs seeking to demonstrate comparability with confidence.
Biosimilars workflows supported by Gyrolab
Gyrolab is used across preclinical and clinical workflows where precise, reproducible ligand-binding data are critical, including:
- Analytical comparability (binding and potency assays)
- PK bioanalysis
- Immunogenicity (ADA and NAb assays)
- Biomarker quantification
- Titer analysis
- Impurity analysis
Gyrolab® 2G Generic PK Kit
Gyrolab 2G Generic PK immunoassay Kit: quantitation of human therapeutic mAbs (IgG1, IgG2, IgG4) in animal matrices for preclinical pharmacokinetic studies
Explore Gyrolab 2G generic PK Kit](/content/immunoassays/products/gyrolab-2g-generic-pk-kit/index.html)
Gyrolab Generic PK Kit
Gyrolab Generic PK immunoassay Kit: quantitation of human therapeutic mAbs (IgG1, IgG2, IgG4) in animal matrices for preclinical pharmacokinetic studies
Explore Gyrolab generic PK Kit](/content/immunoassays/products/gyrolab-generic-pk-kit/index.html)
Gyrolab® Generic Cyno ADA Kit Reagents
Screen biotherapeutics in early development using Gyrolab Generic Cyno ADA Kit Reagents for detection of circulating human IgG:cyno IgG immune complexes](/content/immunoassays/products/gyrolab-generic-cyno-ada-kit-reagents/index.html)
Gyrolab® Generic Rodent ADA Kit Reagents
Screen biotherapeutics in early development using Gyrolab Generic Rodent ADA Kit Reagents for detection of circulating human IgG:(rat or mouse) IgG immune complexes](/content/immunoassays/products/gyrolab-generic-rodent-ada-kit-reagents/index.html)
Gyrolab vs ELISA for biosimilar analysis
Time to results
Results in just over an hour, compared to several hours or overnight with ELISA.
.png)
Hands-on time
Automated processing reduces manual pipetting and intervention.
.png)
Dynamic range
Fewer dilutions are needed to bring samples into range.
.png)
Matrix tolerance
The flow-through format reduces background in complex matrices such as serum.
.png)
Sample volume
Nanoliter-scale assays require significantly smaller sample volumes than plate-based methods.
Throughput and runs required
Higher pass rates and faster runtimes reduce repeat burden keeping your project timelines on track.
Validation and data confidence
Gyrolab is used in bioanalytical preclinical and clinical environments where data integrity, traceability, and reproducibility matter. Automated workflows reduce operator-dependent variation, while software support provides audit trails, controlled user access, and structured data handling to support compliance with GLP/GMP expectations.
Assays can be transferred between systems and sites with reproducible results, supporting long-term studies and regulatory submissions without added complexity.
Ready to improve your immunoassay workflow?
Discuss your biosimilar analysis with a Gyrolab specialist and explore how automation could support your timelines and data needs.